Education
Virtual sessions, in-person training and on-demand learning
Live learning
Specialities
Clinical resources organized by practice area
Events
Conferences, workshops, and networking opportunities
Carlos F Muniz, Apeksha V Shenoy, Kathryn L O?Connor, Sophia C Bechek, Emily J Boyle, Mary M Guanci, Tara M Tehan, Sahar F Zafar, Andrew J Cole, Aman B Patel, Michael B Westover, Eric S Rosenthal
Background
The SafeBoosC phase II multicentre randomized clinical trial investigated the benefits and harms of monitoring cerebral oxygenation by near-infrared spectroscopy (NIRS) combined with an evidence-based treatment guideline vs. no NIRS data and treatment as usual in the control group during the first 72 h of life. The trial demonstrated a significant reduction in the burden of cerebral hypoxia in the experimental group. We now report the blindly assessed and analyzed treatment effects on electroencephalographic (EEG) outcomes (burst rate and spectral edge frequency 95% (SEF95)) and blood biomarkers of brain injury (S100?, brain fatty acid-binding protein, and neuroketal).
